Compare Bank of America Corp (BAC) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of America Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Bank of America Corp trades at $60.8 (market cap $425.43B), while Regeneron Pharmaceuticals Inc trades at $655.02 (market cap $68.79B). The key difference: Bank of America Corp is far larger — about 6.2× Regeneron Pharmaceuticals Inc's market cap, and Bank of America Corp pays the higher dividend (1.85%). Which is the better fit depends on your goals.
| BAC | REGN | |
|---|---|---|
Market Cap | $425.43B | $68.79B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $60.62 | $812.27 |
52-Week Low | $44.92 | $542.52 |
Dividend Yield | 1.85% | 0.57% |
Enterprise Value | — | $62.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $60.62, up 1.59% today, with a bullish technical signal from moving averages and a consensus analyst price target of $63.79. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.11 exceeding expectations. Revenue grew to $113.10 billion in 2025, and the company maintains a strong deposit franchise, as highlighted by recent news coverage.
The outlook is positive, supported by earnings momentum and potential capital returns post-stress tests. Risks include macroeconomic sensitivity and regulatory changes. Analyst sentiment is strongly bullish, with 65% recommending Buy.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
